-transparent.png){kind=logo}
The presence of brain metastasis in lung cancer patients is a highly unfavorable event that usually allows only palliative treatment. A retrospective study was conducted to evaluate the prognostic factors in patients with non-small cell lung cancer (NSCLC) associated with brain metastases. From July 1984 through June 1990, a total of 50 patients with NSCLC associated with symptomatic brain metastasis seen at National Taiwan University Hospital were included. Patients who had incomplete cancer staging workup or loss of follow-up were excluded. Several possible prognostic variables were analyzed initially with univariate analysis and subsequently with multivariate analysis with maximal partial likelihood ratio test in the Cox model. In the univariate analysis, several factors, including number of brain metastases, treatment for brain metastasis with brain tumor resection (BTR) or whole brain radiation therapy (WBRT), and chemotherapy (C/T) after brain metastasis were found to have significant influence on the survival. However, in the multivariate analysis, patients receiving BTR, WBRT, and/or C/T lived significantly longer. The median survival of patients treated with BTR was nine months, eight months in patients with C/T, and seven months in patients with WBRT. Taken together, these patients had a median survival of seven months, which was significantly longer than patients treated with supportive care only (with a median survival of two months). Treatment of brain metastases with WBRT, BTR, C/T, or in combinations also improved the quality of life. We conclude that NSCLC patients with brain metastases should be more aggressively treated with WBRT, BTR, C/T, or in combinations than supportive care only.
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
June 2011,
Clinical oncology (Royal College of Radiologists (Great Britain)),
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
August 2013,
Current oncology (Toronto, Ont.),
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
July 2003,
Current oncology reports,
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
February 2003,
Current treatment options in oncology,
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
September 2013,
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
January 2016,
Contemporary oncology (Poznan, Poland),
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
August 2016,
Zhongguo fei ai za zhi = Chinese journal of lung cancer,
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
May 2013,
Thoracic cancer,
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
September 2005,
Oncology reports,
D B Chang, and
P C Yang, and
K T Luh, and
S H Kuo, and
R L Hong, and
L N Lee
March 2010,
Current opinion in oncology,
